Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) shares dropped 5.6% on Thursday . The stock traded as low as $2.20 and last traded at $2.20. Approximately 210,469 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 1,070,862 shares. The stock had previously closed at $2.33.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Price Performance

The company has a market cap of $590.72 million, a P/E ratio of -1.83 and a beta of 2.05. The company’s 50-day moving average is $2.70 and its two-hundred day moving average is $3.56.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the firm earned ($0.26) EPS. On average, analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently modified their holdings of the company. Wellington Management Group LLP grew its position in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC raised its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Great Point Partners LLC lifted its stake in Autolus Therapeutics by 195.0% in the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after acquiring an additional 1,578,000 shares during the last quarter. Finally, Affinity Asset Advisors LLC lifted its position in Autolus Therapeutics by 27.4% in the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.